In line with that, a large genome-wide association study showed that the Pi*Z variant is associated with 2–3 times increased odds for alcohol-associated liver disease–related/metabolic dysfunction–associated steatotic liver disease–related cirrhosis, thereby surpassing the risks conferred by established genetic liver disease modifiers, for example, PNPLA3 p. Ile148Met (rs738409), hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13):T (rs72613567), and TM6SF2 p. Glu167Lys (rs5854926).83 This evidence concerns the gene HSD17B13 and Cirrhosis.